Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy

Treatment of patients with B-NHL with rituximab and CHOP has resulted in significant clinical responses. However, a subset of patients develops resistance to further treatments. The mechanism of unresponsiveness in vivo is not known. We have reported the development of rituximab-resistant clones der...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Int J Oncol
Main Authors: VEGA, GABRIEL G., FRANCO-CEA, LUZ ARELI, HUERTA-YEPEZ, SARA, MAYANI, HÉCTOR, MORRISON, SHERIE L., BONAVIDA, BENJAMIN, VEGA, MARIO I.
Format: Artigo
Sprog:Inglês
Udgivet: D.A. Spandidos 2015
Fag:
Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4735703/
https://ncbi.nlm.nih.gov/pubmed/26398317
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2015.3170
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker